Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Cellular and Molecular Life Sciences : CMLS|July 31, 2019
Versatile cell ablation tools and their applications to study loss of cell functionsFengming Liu, Shen Dai, Dechun Feng, et al.
Cancers|January 20, 2019
Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer CellsChun-Yu Liu, Pei-Yi Chu, Chun-Teng Huang, et al.
Cancer Research|March 5, 2009
Cancer-specific transgene expression mediated by systemic injection of nanoparticlesEdward J Chisholm, Georges Vassaux, Pilar Martin-Duque, et al.
Diabetology & Metabolic Syndrome|October 4, 2025
Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patientsMing-Hsun Lin, Ren-Hua Ye, Hong-Jie Jhou, et al.
Nature Medicine|October 1, 2024
Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trialBinghe Xu, Shusen Wang, Min Yan, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 25, 2022
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-respondersPo-Han Lin, Ling-Ming Tseng, Yi-Hsuan Lee, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|December 3, 2014
Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in TaiwanChing-Hsun Wang, Li-Ping Kan, Hsin-An Lin, et al.
Cell Death & Disease|October 6, 2021
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistanceYi-Ying Wu, Hsing-Fan Lai, Tzu-Chuan Huang, et al.
Elife|January 21, 2025
Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastasesShih-Wen Huang, Yein-Gei Lai, Hao-Ting Liao, et al.
Journal of Clinical Medicine|April 23, 2022
Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid TumorsChien-Chang Kao, Ching-Liang Ho, Ming-Hsin Yang, et al.
Pageof 13